Daratumumab-hyaluronidase-fihj · Hematology-Oncology
Darzalex Faspro (J9144) carries a median commercial contracted rate of 98.6 on the Medicare ASP=100 index — 4.0% below the 102.7 typical-acquisition benchmark and 5.5% below the 104.3 Medicare payment line. 58 insurers report contracted rates across 52 states (1,020 priced cells), covering $2.31B in modeled Part B spend. It ranks #19 of 25 on the CareCost Buy-and-Bill Risk List, with a risk score of 68.7 out of 100.
Shaded band: 10th–90th percentile across insurers. Darker band: 25th–75th percentile. Solid tick: median. Dashed lines: 100 (Medicare ASP), 102.7 (typical acquisition cost), 104.3 (Medicare payment after sequestration), 100.2 (NADAC-measured acquisition, see below).
All 49 insurers with published rates for this code, ranked highest to lowest. Index is a multiple of Medicare ASP (ASP=100).
Medicare's payment limit for Darzalex Faspro moved +22.2% between Q1 2022 and Q2 2026. Because contracted rates are set as a multiple of ASP, a rising denominator lifts every contracted rate tied to it.
Solid dots: finalized CMS ASP quarters. Hollow dots: preliminary. Values are the Medicare payment limit (ASP + 6%, pre-sequestration) per billing unit.
| Year | Part B spend | Dosage units (M) |
|---|---|---|
| 2021 | $1.05B | 23.6 |
| 2022 | $1.58B | 34.9 |
| 2023 | $2.08B | 43.8 |
| 2024 | $2.53B | — |
| 2025 | $2.31B | — |
NADAC-measured acquisition cost for Darzalex Faspro runs $52.03/unit as of n/a — an acquisition index of 100.2 (ASP = 100).
At the median contracted index of 98.6, that implies a modeled gross margin of -1.6 points per ASP-unit — roughly −$0.86/unit at the latest ASP of $53.82.
Modeled from NADAC acquisition, high confidence — your invoice price governs.
| Highest-paying states | Index | Insurers |
|---|---|---|
| Alaska (AK) | 114.8 | 7 |
| Idaho (ID) | 107.9 | 11 |
| Utah (UT) | 105.6 | 11 |
| South Dakota (SD) | 105.2 | 8 |
| Nebraska (NE) | 104.7 | 9 |
| Lowest-paying states | Index | Insurers |
|---|---|---|
| Maryland (MD) | 96.5 | 13 |
| Kentucky (KY) | 96.5 | 13 |
| Rhode Island (RI) | 96.5 | 9 |
| New Jersey (NJ) | 96.5 | 13 |
| Maine (ME) | 96.5 | 10 |
At the median contracted rate, this code models a −$3,988 shortfall per $100,000 of acquisition-benchmark drug cost purchased — illustrative modeled margin exposure, not a claim about any single practice's actual reimbursement.
Based on 1,020 priced contract cells across 58 insurers and 52 states. These are insurers' contracted rates from published machine-readable files — not amounts actually paid on a claim, and not a guarantee of coverage or reimbursement. CareCost Estimate Infusion Reimbursement Index, Issue 01 (Q2 2026), v2.0. CC-BY 4.0.
See also: Reblozyl · Tecentriq · Enhertu · report home · methodology